169.4700 -3.80 (-2.19%)
NSE Aug 28, 2025 15:31 PM
Volume: 912.5K
 

169.47
-2.19%
Dynamic Levels
Marksans R&D; capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development and conducting stability studies. The company has a team of over 50 experienced scientists specializing in formulation development and analytical development. The conpany has possessed end-to-end capabilities from Lab scale development to Pilot scale up and from commercializing the product for large...
Number of FII/FPI investors increased from 153 to 159 in Jun 2025 qtr.
More from Marksans Pharma Ltd.
Recommended